AstraZeneca is to raise $3.5 billion to fund a global development and marketing collaboration with Daiichi Sankyo, for an antibody-drug conjugate and potential new targeted cancer medicine,
Daiichi Sankyo’s Lixiana was a late entrant to the novel oral anticoagulant (NOAC) category, but the Japanese drugmaker hopes new data in atrial fibrillation (AFib) could accelerate its gro
Daiichi Sankyo has been given a priority review from the FDA for pexidartinib, which is vying to become the first systemic drug therapy for rare cancer tenosynovial giant cell tumour (TGCT).
Japan’s Daiichi Sankyo has joined an open innovation research initiative that will try to develop a therapy for type 1 diabetes based on insulin-producing cells.
Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data
The Life Sciences Generative AI Council aims to bring together the best minds in pharma, academia, and technology to advance the use of GenAI in life sciences R&D, seeking through pinpo